$1.05
1.87% yesterday
Nasdaq, Oct 15, 10:08 pm CET
ISIN
US19188J3005
Symbol
COCP

Cocrystal Pharma Inc Stock price

$1.05
-0.38 26.57% 1M
-0.29 21.64% 6M
-0.97 48.02% YTD
-0.78 42.70% 1Y
-1.39 56.97% 3Y
-9.99 90.49% 5Y
-272.55 99.62% 10Y
+0.95 950.00% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.02 1.87%
ISIN
US19188J3005
Symbol
COCP
Industry

Key metrics

Basic
Market capitalization
$13.7m
Enterprise Value
$8.9m
Net debt
positive
Cash
$4.8m
Shares outstanding
10.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
70.8%
Return on Equity
-189.0%
ROCE
-190.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-12.6m | $-17.5m
EBIT
$-12.7m | $-10.5m
Net Income
$-12.6m | $-8.5m
Free Cash Flow
$-13.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
32.0% | 2.2%
EBIT
32.0% | 41.9%
Net Income
29.9% | 52.6%
Free Cash Flow
6.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.2
FCF per Share
$-1.3
Short interest
2.5%
Employees
11
Rev per Employee
$0.0
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cocrystal Pharma Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Cocrystal Pharma Inc forecast:

Buy
88%
Hold
13%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.96 4.96
11% 11%
-
- Research and Development Expense 7.76 7.76
51% 51%
-
-13 -13
32% 32%
-
- Depreciation and Amortization 0.10 0.10
38% 38%
-
EBIT (Operating Income) EBIT -13 -13
32% 32%
-
Net Profit -13 -13
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, October 9, 2025 at 12:00 pm Eastern time (9:00 a.m.
Neutral
GlobeNewsWire
about one month ago
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants
Neutral
GlobeNewsWire
about one month ago
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants
More Cocrystal Pharma Inc News

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today